

AMENDMENT SUBMISSION FORM

INSTITUTIONAL REVIEW BOARD

OFFICE OF RESEARCH SERVICES

Room S144 MC 1108

5841 S. Maryland Ave., Chicago, Illinois 60637

Phone: 773-702-6505 / Fax 773-834-0659

http://ors.bsd.uchicago.edu/HS

Protocol Number	For Office Use Only Amendment #
and form, co-investigators, other research recruitment, requires the submission of an A made and the rationale for the change. The	mmendment. Please clarify the change(s) to be revised protocol, consent form, with the changes clearly identified, using a ster or additional information may also be and if the revised portions of the pertinent
Amendments to protocols may not be initiated	until IRB approval has been obtained.
PRINCIPAL INVESTIGATOR Last Name	First Name
The following changes are proposed for this Principal Investigator change Please list the name of the new Principal	
Last Name	
First Name BSD ID# -	
Co-Investigator change If you are adding or removing a coinve complete and submit supplemental form Other research personnel change If you are adding or removing a member a coinvestigator), please complete and Primary contact change	A of the investigative staff (other than
Last Name	
First Name	

BSD ID#

New Protocol Title Drug If a drug is being added to the prot	
If a drug is being added to the prot	
	ocol please submit the Supplemental Form D .
Device	
	otocol please submit the Supplemental Form F.
Study population	There of dubicates
Age Range (check all that apply) 0-7 yrs.	Type of Subjects inpatients
	— □ outpatients
	healthy volunteers
18-58 yrs.	UC employees
59+ yrs.	UC Students
	_
_	n the research (check all that apply):
minors under age 18 - Supplement	al form C must be included
pregnant women	
☐ fetus/fetal tissue	
☐ prisoners	
economically disadvantaged	
decisionally impaired	
mentally retarded	
illiterate	
Non-English speaking	
umber of Subjects	
lease indicate the number of additiona n addition, please indicate the new to	l subjects to be recruited into the study. tal number of subjects.
To be added Total	l number of subjects
If an increase in the number of subjection the increase.	cts is requested, please provide a justification

1.	Is a revised protocol necessary as a result of this amendment?	Yes	□ No*
	If yes, please attach the revised protocol and clarify the following		
	Version # Version Date		
2.	Is a revised consent form necessary as a result of this amendment?	Yes	□ No*
	If yes, please attach the revised consent form and clarify the following		
	Version # Version Date		
	Version # Version Date		
3.	Is a revised advertisement necessary as a result of this amendment?	Yes	No
	If yes, please attach the revised advertisement.		
4.	Is a revised Investigator Brochure necessary as a result of this amendment?	Yes	☐ No
	If yes, please attach the revised Investigator Brochure and clar	ify the fo	llowing:
	Version # Version Date		
5.	Is a change in drug dosage (increase or decrease) being proposed? If yes, a revised protocol must be sent to the Dept. of	Yes	☐ No
	Pharmaceutical Services, Section of Investigational Drugs (MC 0010) once the dose changes are approved by the IRB.		
		decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use
	(MC 0010) once the dose changes are approved by the IRB. Please describe the specific changes to the previously approved protosufficient rationale for each change to allow the committee to make a additional pages as necessary. *If a revised protocol and/or revised	decision. d consent f	Use

		risks to	, subj	CCCS	arrect	.eu (.	IIICI	case	a or	ac	CIC	ascu	., Dy		Y	es		No
If	yes,	describe	e how	the a	mendme	ent w	ill	affe	ct tł	1e	ris	k-be	nefit	t ra	tio	for	the	subjec
Rea	ffirm	mation of	Info	rmed	Consen	nt/Ass	sent	:										
		ecessary Date in t								ady	7 CO	nsen	ted t	to	[Ye	:S	☐ No
for	m OR	should ton with	an add the s	endum ubjec	to th	ne in: S elec t	form t On	ned c	onser			umen	t be	pre				nsent
		Full F	Revise	d Inf	ormed	Cons	ent	Docu	ment		L	Add	lendur	m				
Not	ifica	tion of	Subje	cts W	ho Hav	e Cor	mple	eted	Parti	Lci	.pat	ion						
		ecessary pation in				cts wl	ho h	nave	comp]	Let	ed	thei	r			Ye	:S	No
		describe	e how	this	will b	oe dor	ne A	AND s	ubmit	t t	he	docu	ments	s (i	f ar	plic	cable	e) that
.Is	exped	lited rev	view b	eing	reques	sted?										Ye	:S	☐ No
thr sim ris	ough ple a	the feder an expect administration nefit rationally):	dited cative	proce chan	ss. Th ges an	ne IRI nd min	B ha nor	as ag adju	reed stmer	th nts	nat s wh	the ich	follo do no	owin ot a	g ty ffe	pes ct tl	of ne	
]Addi	ng or re	movin	g an	instit	utior	n											
] Chan	ges in t	he PI															
] Chan	ges in F	artic	ipant	S													
] Addi	ng a sta	ndard	ized	(valid	ated)) qu	esti	onnai	re								

7. Risk-Benefit Assessment

	Submission of or modification to investigational brochures;
	 Modifications to the consent form to include the following: 1) Adding or removing information from the consent form so that it is consistent with an already approved IRB statement (i.e. cost section, phone number changes); 2) revising the consent form to reflect what was already approved in the protocol; 3) defining a phrase(s) more clearly in lay language; or 4) incorporating in the consent form updated IRB-mandated language.
	Minor editorial changes to the protocol and/or consent form which do not alter the meaning or procedures (i.e., spelling changes, revising a statement)
	Removal of a questionnaire from protocol and its reference on consent form.
	Software Upgrades
	addition, if the original protocol was reviewed through an expedited review ocedure, the amendment MAY be eligible for expedited review. Please check here if the original protocol was given expedited approval.
l –	SIGNATURE
((This form must bear the original signature of the principal investigator)
	Principal Investigator Date
	Department Chair Signature Date (Only if not externally funded)